Kezar Life Sciences (NASDAQ:KZR) Rating Reiterated by Cowen

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “buy” rating reiterated by research analysts at Cowen in a report issued on Wednesday, AnalystRatings.com reports.

Several other research analysts have also weighed in on KZR. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Kezar Life Sciences in a research note on Monday, October 21st. ValuEngine upgraded shares of Kezar Life Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research lowered shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $9.25.

Kezar Life Sciences stock traded down $0.03 during trading hours on Wednesday, hitting $2.89. The company had a trading volume of 27,200 shares, compared to its average volume of 94,239. The firm has a market capitalization of $55.12 million, a P/E ratio of -1.28 and a beta of 0.88. The company has a debt-to-equity ratio of 0.06, a current ratio of 20.32 and a quick ratio of 20.32. The firm’s fifty day moving average is $3.28 and its 200-day moving average is $7.82. Kezar Life Sciences has a fifty-two week low of $2.74 and a fifty-two week high of $36.33.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.03. Analysts anticipate that Kezar Life Sciences will post -1.96 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY acquired a new position in shares of Kezar Life Sciences during the 1st quarter worth $89,000. Acadian Asset Management LLC acquired a new position in shares of Kezar Life Sciences during the 2nd quarter worth $107,000. A.R.T. Advisors LLC acquired a new position in shares of Kezar Life Sciences during the 2nd quarter worth $112,000. Ironsides Asset Advisors LLC increased its stake in shares of Kezar Life Sciences by 50.0% during the 2nd quarter. Ironsides Asset Advisors LLC now owns 17,650 shares of the company’s stock worth $136,000 after purchasing an additional 5,886 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of Kezar Life Sciences by 302.5% during the 2nd quarter. Wells Fargo & Company MN now owns 30,878 shares of the company’s stock worth $238,000 after purchasing an additional 23,207 shares during the last quarter. Institutional investors own 52.28% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Featured Article: What is a Tariff?

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.